Ningbo Cancer Hospital

Company snapshot

Ningbo Cancer Hospital maintains 120 tracked programs across Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carcinoma, Early stage HER2-positive breast cancer, Localized ER+ breast cancer, BRAF(V600) mutation-positive melanoma with brain metastasis (MBM), Metastatic hormone naïve prostate cancer (mHNPC), HER2+ metastatic breast cancer with

• 120 active pipeline program(s) linked via ClinicalTrials.gov.
• 120 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ningbo Cancer Hospital. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ningbo Cancer Hospital.

1. Jun 8, 2026 Clinical update

   EORTC 1740-HNCG — Phase 2

2. Jun 8, 2026 Clinical update

   IMFINZI for Advanced Biliary Cancer (ABC) — Phase 3

3. Jun 8, 2026 Clinical update

   UC-0160/1003 — Phase 3

4. Jun 8, 2026 Clinical update

   SAKK 38/19 — Phase 2

5. Jun 8, 2026 Clinical update

   GINECO-OV244b — Phase 2

View all clinical trial activity →

• What is Ningbo Cancer Hospital?

  Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carcinoma, Early stage HER2-positive breast cancer, Localized ER+

• Is Ningbo Cancer Hospital publicly traded?

  Ningbo Cancer Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ningbo Cancer Hospital develop or market?

  We link 183 drug profile(s) where Ningbo Cancer Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cancer-prevention-pharma-ireland-limited#company-drugs.

• What are the latest developments for Ningbo Cancer Hospital?

  In the last 12 months our linked public records show 120 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ningbo Cancer Hospital focus on?

  Ningbo Cancer Hospital focuses on Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carcinoma based on our analysis of their pipeline programs and drug development activities.